PEN · CIK 1321732
What Penumbra, Inc. told the SEC could break it.
The overhang on Penumbra's register is its pending acquisition by Boston Scientific, which depends on stockholder approval, antitrust and regulatory clearances and other conditions outside its control — a failure to close could pressure its share price, and the agreement carries a $525.0 million termination fee payable by Penumbra (against a $900.0 million reverse fee from Boston Scientific). Beneath that deal, it operates as a medical-device maker subject to FDA and foreign regulatory approval (22.2% of 2025 sales are outside the U.S.), with U.S. demand resting on hospitals' reimbursement from Medicare, Medicaid and private payors, exposing it to coverage and pricing-policy shifts. It also flags raw-material supply risk, particularly where an input comes from a single supplier, which it manages through close collaboration and some long-term contracts.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- pending Boston Scientific merger completion risk (termination fees $525M / $900M)medium
Penumbra's pending acquisition by Boston Scientific is subject to stockholder approval, antitrust/regulatory clearances and other conditions beyond its control; failure to close could depress its share price, and the agreement carries a $525.0M termination fee payable by Penumbra (and a $900.0M reverse fee payable by Boston Scientific) in defined circumstances.
“under circumstances defined in the Merger Agreement, we may be required to pay Boston Scientific Corporation a termination fee of $525.0 million in the event the Merger is not completed.”
SEC filing →As of 2026
Regulatory & policy
- FDA/foreign device regulation and third-party-payor reimbursement (Medicare/Medicaid)medium
Penumbra's products require FDA approval/clearance and foreign regulatory approvals (22.2% of 2025 sales are ex-US); US demand depends on hospitals' reimbursement from third-party payors such as Medicare, Medicaid and private insurers, exposing it to coverage and pricing-policy changes.
“In the United States, hospitals are the primary purchasers of our products. Hospitals in turn bill various third-party payors, such as Medicare, Medicaid and private health insurance plans, for the total healthcare services required to treat the patient.”
SEC filing →As of 2026
Sole-source dependency
- single-supplier raw materials riskmedium
Penumbra faces raw-materials supply risk particularly where an input is provided by a single supplier, which could impair availability in sufficient quantities; it mitigates via close supplier collaboration and some long-term supply contracts.
“However, there are risks and uncertainties with respect to the supply of raw materials, particularly where provided by a single supplier, which could impact availability in sufficient quantities to meet our needs.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“Under the terms of the Merger Agreement, subject to the terms and conditions set forth in the Merger Agreement, our stockholders will have the right to elect, for each share of our common stock held by them, to receive $374 in cash or 3.8721 shares of Boston Scientific Corporation's common stock... The Merger is expected to close by the end of 2026, subject to customary closing conditions, including approval by our stockholders and regulatory approvals.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch